Senseonics (NYSE:SENS) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Senseonics (NYSE:SENS) in a research note issued to investors on Friday. The firm set a “sell” rating on the stock.

Senseonics Stock Performance

Shares of SENS stock traded down $0.01 on Friday, hitting $0.51. 1,500,591 shares of the company’s stock traded hands, compared to its average volume of 2,443,058. The stock has a market cap of $268.49 million, a PE ratio of -4.60 and a beta of 0.91. The firm’s fifty day moving average is $0.53. Senseonics has a one year low of $0.38 and a one year high of $1.05. The company has a quick ratio of 7.03, a current ratio of 7.53 and a debt-to-equity ratio of 1.15.

Senseonics (NYSE:SENS) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.01. The business had revenue of $8.00 million during the quarter, compared to analyst estimates of $7.62 million. Senseonics had a negative net margin of 270.13% and a negative return on equity of 146.90%. As a group, sell-side analysts anticipate that Senseonics will post -0.13 earnings per share for the current fiscal year.

Institutional Trading of Senseonics

A number of institutional investors have recently made changes to their positions in the stock. Cornerstone Wealth Management LLC boosted its holdings in shares of Senseonics by 55.9% during the third quarter. Cornerstone Wealth Management LLC now owns 55,750 shares of the company’s stock worth $34,000 after purchasing an additional 20,000 shares during the period. RPO LLC purchased a new stake in Senseonics in the 4th quarter worth approximately $37,000. Ausdal Financial Partners Inc. lifted its holdings in Senseonics by 53.2% in the 3rd quarter. Ausdal Financial Partners Inc. now owns 72,000 shares of the company’s stock worth $43,000 after buying an additional 25,000 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Senseonics by 30.2% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock worth $483,000 after buying an additional 211,128 shares during the last quarter. Hedge funds and other institutional investors own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.